5
views
0
recommends
+1 Recommend
2 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Prevalence, characteristics and challenges of late HIV diagnosis in Germany: an expert narrative review

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Purpose

          We aimed to review the landscape of late HIV diagnosis in Germany and discuss persisting and emerging barriers to earlier diagnosis alongside potential solutions.

          Methods

          We searched PubMed for studies informing the prevalence, trends, and factors associated with late HIV diagnosis in Germany. Author opinions were considered alongside relevant data.

          Results

          In Germany, older individuals, heterosexuals, and migrants living with HIV are more likely to be diagnosed late. The rate of late diagnosis in men who have sex with men (MSM), however, continues to decrease. Indicator conditions less often prompt HIV testing in women and non-MSM. During the COVID-19 pandemic, the absolute number of late diagnoses fell in Germany, but the overall proportion increased, probably reflecting lower HIV testing rates. The Ukraine war and subsequent influx of Ukrainians living with HIV may have substantially increased undiagnosed HIV cases in Germany. Improved indicator testing (based on unbiased assessments of patient risk) and universal testing could help reduce late diagnoses. In patients who receive a late HIV diagnosis, rapid treatment initiation with robust ART regimens, and management and prevention of opportunistic infections, are recommended owing to severely compromised immunity and increased risks of morbidity and mortality.

          Conclusion

          Joint efforts are needed to ensure that UNAIDS 95-95-95 2030 goals are met in Germany. These include greater political will, increased funding of education and testing campaigns (from government institutions and the pharmaceutical industry), continued education about HIV testing by HIV experts, and broad testing support for physicians not routinely involved in HIV care.

          Related collections

          Most cited references61

          • Record: found
          • Abstract: not found
          • Article: not found

          Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

            Effective two-drug regimens could decrease long-term drug exposure and toxicity with HIV-1 antiretroviral therapy (ART). We therefore aimed to evaluate the efficacy and safety of a two-drug regimen compared with a three-drug regimen for the treatment of HIV-1 infection in ART-naive adults.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found

              Enhanced Prophylaxis plus Antiretroviral Therapy for Advanced HIV Infection in Africa

              In sub-Saharan Africa, among patients with advanced human immunodeficiency virus (HIV) infection, the rate of death from infection (including tuberculosis and cryptococcus) shortly after the initiation of antiretroviral therapy (ART) is approximately 10%.
                Bookmark

                Author and article information

                Contributors
                hartmut.stocker@sjk.de
                Journal
                Infection
                Infection
                Infection
                Springer Berlin Heidelberg (Berlin/Heidelberg )
                0300-8126
                1439-0973
                20 July 2023
                20 July 2023
                2023
                : 51
                : 5
                : 1223-1239
                Affiliations
                [1 ]Department of Medicine, University Hospital Bonn, ( https://ror.org/01xnwqx93) Bonn, Germany
                [2 ]Novopraxis Berlin GbR, Berlin, Germany
                [3 ]School of Medicine, University Hospital Rechts der Isar, Technical University of Munich, ( https://ror.org/02kkvpp62) Munich, Germany
                [4 ]Department of Infectious Diseases, University Hospital Frankfurt, ( https://ror.org/03f6n9m15) Frankfurt, Germany
                [5 ]Department of Infectious Diseases, St. Joseph Hospital, Berlin, Germany
                Author information
                http://orcid.org/0000-0003-0686-6537
                http://orcid.org/0009-0008-1117-7836
                http://orcid.org/0000-0002-0300-0159
                http://orcid.org/0000-0001-6828-4116
                http://orcid.org/0000-0001-9656-8474
                Article
                2064
                10.1007/s15010-023-02064-1
                10545628
                37470977
                e469feef-7221-4e1e-b854-621f18c7b9b7
                © The Author(s) 2023

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 4 April 2023
                : 10 June 2023
                Categories
                Review
                Custom metadata
                © Springer-Verlag GmbH Germany, part of Springer Nature 2023

                Infectious disease & Microbiology
                late hiv diagnosis,germany,covid-19,ukraine war,universal testing,indicator testing,art

                Comments

                Comment on this article